Regulatory Reform 2024 of Drugs（1）

In December 2024, the General Office of the State Council issued the "Opinions on Comprehensively Deepening the Regulatory Reform of Drugs and Medical Devices and Promoting the High-quality Development of the Pharmaceutical Industry" (Guo Ban Fa [2024] No. 30), which was released on December 30, 2024, and the main contents include: improving the relevant systems for the protection of intellectual property rights of drugs and medical devices, actively supporting the promotion and use of innovative drugs and medical devices, increasing the support for R&D and innovation of traditional Chinese medicine, and improving the quality and efficiency of the review and approval of drugs and medical devices. Improve the compliance level of the pharmaceutical industry with efficient and strict supervision, support the pharmaceutical industry to expand opening up and cooperation, and explore the segmented production model of biological products